Aytu BioPharma, Inc. Appoints Abhinav "Abi" Jain to the Board of Directors
June 09, 2023 at 08:36 am EDT
Share
Aytu BioPharma, Inc. announced the appointment of Abhinav "Abi" Jain of Nantahala Capital Management, LLC as the Company's Board of Directors as Board of Directors. In connection with Mr. Jain's appointment to the
Board, upon the closing of the Offering, Mr. Jain will be appointed to the Company's Audit Committee, Compensation Committee, and Nominating and Governance Committee. Abi Jain is an Analyst at Nantahala, focused on investments in various sectors, including specialty and generic pharmaceuticals. Prior to joining Nantahala in 2019, Mr. Jain was an Associate at Angelo, Gordon &Co., an alternative asset manager based in New York from 2015-2017. At Angelo, Gordon &Co., Mr. Jain focused on private equity and structured credit investments. He graduated from Massachusetts Institute of Technology in 2012 with an S.B. in Chemical-Biological Engineering and from The Wharton School of the University of Pennsylvania in 2019 with an M.B.A. with honors in Finance and Entrepreneurial Management.
Aytu BioPharma, Inc. is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Companyâs Rx segment consists of prescription pharmaceutical products and the Consumer Health segment consists of various consumer healthcare products (the Consumer Health Portfolio). The Companyâs prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (ADHD); Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions; and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Its Consumer Health Segment addresses a range of common conditions.